

CIN No.: L99999MH1990PLC056538

H. O.: 107,204, SAHAKAR BHAVAN, 340 / 48, N. N. STREET, MASJID BUNDER, MUMBAI - 400 009. ©: (022) 66312998 / 66154219 Fax: 66154219 E-mail: info@aareydrugs.com REGD. OFF. & FACTORY: E - 34, M.I.D.C., TARAPUR, BOISAR, DIST - THANE - 401506 ©: (02525) 271049 E-mail: corporate@aareydrugs.com Web: www.aareydrugs.com

Date: 15th February, 2016

To,
Department of Corporate Services,
Bombay Stock Exchange,
1st Floor, P.J. Towers,
Dalal Street, Fort,
Mumbai – 400001.

Dear Sir,

Sub: Outcome of Board Meeting held on 15th February, 2016.

Scrip Code: 524412

This is to inform you that the Board of Directors of the company at its Meeting held today, i.e. 15th February, 2016, have passed the following resolutions:

The Board of Directors of the company has considered the Unaudited financial results for the Quarter & 9 months ended 31st December, 2015.

Kindly take record of the above.

Thanking You,

For Aarey Drugs and Pharmaceuticals Limited

Managing Director



EZZZOJJ90ECIHMERERELI.ON NIJ

H. O. : 107,204, SAHAKAR BHAVAN, 340 / 48, N. N. STREET, MASJID BUNDER, MUMBAI - 400 009. © : (022) 66312998 / 66154219 Fax : 66154219 E-mail : info@aareydrugs.c REGD. OFF. & FACTORY : E - 34, M.I.D.C., TARAPUR, BOISAR, DIST - THANE - 401506 © : (02525) 271049 E-mail : corporate@aareydrugs.com Web : www.aareydrugs.c

15th February,2016

To, Dept. of Corporate Services The Bombay Stock Exchange Ltd 1st floor, Rotunda Building, M.S.Marg, Mumbai-400 001.

Sub: UN-AUDITED QUARTERLY RESULT (CLAUSE 41) FOR THE QUARTER ENDED 31st DECEMBER,2015

Dear Sir,

Pursuant to listing agreement we are enclosing herewith the Un-audited financial results for the quarter ended 31st December,2015 with limited review report of the auditors & Annexure for Consolidated - Division Wise.

Kindly acknowledge the same & oblige.

Thanking You,

Yours faithfully,

For Aarey Drugs & Pharmaceuticals Ltd

Encl.: a/a



CIN No. L99999MH1990PLC056538

H. O. : 107,204, SAHAKAR BHAVAN, 340 / 48, N. N. STREET, MASJID BUNDER, MUMBAI - 400 009. © : (022) 66312998 / 66154219 Fax : 66154219 E-mail : info@aareydrugs.com REGD. OFF. & FACTORY : E - 34, M.I.D.C., TARAPUR, BOISAR, DIST - THANE - 401506 © : (02525) 271049 E-mail : corporate@aareydrugs.com Web : www.aareydrugs.com

						,	₹ In Lacs
Sr No.	PARTICULARS	3 MONTHS ENDED			9 MONTHS ENDED		YEAR ENDE
		31.12.2015 Unaudited	30.09.2015 Unaudited		31.12.2015 Unaudited	31.12.2014 Unaudited	31.03.2015 Audited
1		6308.36	3160.67	5182.54	13526.62	13235.65	20967.17
2	Cost of Sales/Services a. Increase/Decrease in stock in						
	trade & work in progress						
	b. Consumption of Raw Materials						
	c. Purchase of traded goods						
	d. Other Expenditure	24.74		94.08	212.76	389.47	376.97
3	Gross Profit (1-2)	24.71	60.69	20.66	143.20	148.65	211.59
4	General Administrative Expenses	29.05	44.10		49.96	34.91	55.09
5	Selling and Distribution Expenses	26.02	10.06	12.68		42.54	105.33
6	Depreciation	22.31	21.87	22.41	66.06		4.96
7	Operating Profit before Interest (3) - (4+5+6)	-52.67	-15.34	38.33	-46.46	163.37	
8	Interest	40.28	40.15	29.48	115.74	84.71	123.07
9	Exceptional Items	0	0	0	0	0	0
10		-92.95	-55.49	8.85	-162.2	78.66	-118.11
11		113.02	100.70	6.45	287.57	21.69	259.11
12	Profit (+)/Loss (-) from Ordinary	20.07	45.21	15.30	125.37	100.35	141.00
_	Activities before tax (10+11)	0.00	0.00	0.00	0.00	0.00	32.16
13		0.00		15.30	125.37	100.35	108.84
14	Net Profit (+)/Loss (-) from ordinary Activities after tax (12-13)	20.07	45.21				
15	Extraordinary items (net of tax expenses)	0	0	0	0	0	0
16	Net Profit(+)/Loss(-) for the period(14-15)	20.07	45.21	15.30	125.37	100.35	108.84
17	Paid-up equity share capital-Rs:10/-	1681.4684	1681.4684	1681.4684	1681.4684	1681.4684	
18							1859.44
19	Earning Per Share (EPS) a) Basic and diluted EPS before Extraordinary items for the period, for the year to date and for the previous year (not to be annualized) b) Basic and diluted EPS after Extraordinary items for the period,	0.12	0.27	0.09	0.75	0.60	0.65
20	for the year to date and for the previous year (not to be anualized) Public shareholdingPercentage of Shareholding	7160132 42.58%	7160132 42.58%	7160143 42.58%	7160132 42.58%	7160143 42.58%	716014 42.58%



CINNO L99999MH1990PLC056538

H. O. : 107,204, SAHAKAR BHAVAN, 340 / 48, N. N. STREET, MASJID BUNDER, MUMBAI - 400 009. © : (022) 66312998 / 66154219 Fax : 66154219 E-mail : info@aareydrugs.com REGD. OFF. & FACTORY : E - 34, M.I.D.C., TARAPUR, BOISAR, DIST - THANE - 401506 © : (02525) 271049 E-mail : corporate@aareydrugs.com Web : www.aareydrugs.com

21	Promoters and promoter group						
	Shareholding **						
	a) Pledged/Encumbered						
	Number of Shares	NIL	NIL	NIL	NIL	NIL	NIL
	Percentage of Shares (as a % of						
	the total shareholding of promoter &						
	promoter group)						
	Percentage of shares (as a% of	NIL '	NIL	NIL	NIL	NIL	NIL
	the total share capital of the company)						
	b) Non-encumbered						
	Number of Shares	9654552	9654552	9654541	9654552	9654541	9654541
	Percentage of Shares (as a% of	100.00%	100.00%	100.00%	100.00%	100.00%	100%
	the total shareholding of promoter &						
	promoter group)						
	Percentage of shares (as a % of	57.42%	57.42%	57.42%	57.42%	57.42%	57.42%
	the total share capital of the company)						

Notes :-

- 1) The above financial results have been taken on record by the Board of Director's of the Company at its Board meeting held on 15.02.2016
- 2) Status of investors complaints (Nos): Opening Balance as on 01.10.15 Nil; Received during the quarter 0; Disposed off during the quarter 0; Closing Balance as on 31.12.15 Nil.

Place : Tarapur

Date: 15th February'2016

By Order of the Board of Directors

Mihir R.Ghatalia Managing Director

For AAREY DRUGS & PHARMACEUTICALS LTD.

MANAGING DIRECTOR



CINNO-L99999MH1990PLC056538

H. O. : 107,204, SAHAKAR BHAVAN, 340 / 48, N. N. STREET, MASJID BUNDER, MUMBAI - 400 009. © : (022) 66312998 / 66154219 Fax : 66154219 E-mail : info@aareydrugs.com REGD. OFF. & FACTORY : E - 34, M.I.D.C., TARAPUR, BOISAR, DIST - THANE - 401506 © : (02525) 271049 E-mail : corporate@aareydrugs.com Web : www.aareydrugs.com

AAREY DRUGS & PHARMACEUTICALS LTD

ANNEXURE - I

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 31ST DECEMBER'2015

Sr No.	PARTICULARS	9 MONTHS ENDED 3 MONTHS ENDED					
NO.	PARTICULARS	31.12.2015 31.12.2014		3 MONTHS ENDED 31.12.2015 30.09.2015			
						Unaudited	
		Unaudited	Unaudited	Unaudited	Unaudited	Unaddited	
1	Net Income from Sales/Services	10991.51	9537.57	5066.46	2577.09	3693.63	
2	Cost of Sales/Services	10821.30	9259.16	5046.69	2528.54	3627.78	
	a. Increase/Decrease in stock in						
	trade & work in progress						
	b. Consumption of Raw Materials						
	c. Purchase of traded goods						
	d. Other Expenditure						
3	Gross Profit (1-2)	170.21	278,41	19.77	48.55	65.85	
4	General Administrative Expenses	114.56	104.05	23.24	35.28	14.46	
5	Selling and Distribution Expenses	39.97	24.45	20.82	8.05	8 88	
6	Depreciation	52.98	29.78	17.85	17.50	15.69	
7	Operating Profit before Interest (3) - (4±5+6)	-37.3	120.13	-42.14	-12.28	26.82	
8	Interest	92.60	59.30	32.22	32.12	20.64	
9	Exceptional Items	0	0	0	0	0	
10	Operating Profit after Interest and Exceptional Items (7-8-9)	-129.9	60.83	-74.36	-44.4	6 18	
11	Other Income	230.33	17.91	90.42	80.56	4.52	
12	Profit (+)/Loss (-) from Ordinary	100.43	78.74	16.06	36.16	10.70	
12	Activities before tax (10+11)						
13	Tax Expenses	0.00	0.00	0.00	0.00	0.00	
14	Net Profit (+)/Loss (-) from ordinary	100.43	78.74	16.06	36.16	10.70	
	Activities after tax (12-13)						
15	Extraordinary items (net of tax expenses)	0	0	0	0	0	
16	Net Profit(+)/Loss(-) for the period(14-15)	100.43	78.74	16.06	36.16	10.70	
17	Paid-up equity share capital-Rs.10/-	1681.4684	1681.4684	1681.4684	1681.4684	1681.4684	
18	Reserves excluding revaluation reserves(as per balance sheet) of previous accounting year to be given in column (5)						
19	Earning Per Share (EPS) a) Basic and diluted EPS before Extraordinary items for the period, for the year to date and for the previous year (not to be annualized) b) Basic and diluted EPS after Extraordinary items for the period, for the year to date and for the previous year (not to be anualized)	0.61	0.46	0.10	0.22	0 06	
20	Public shareholdingNumber of sharesPercentage of Shareholding	7160132 42.58%	7160143 42.58%	7160132 42.58%	7047886 41.92%	7160143 42 58%	

Place : Tarapur

Date: 15th February'2016

By Order of the Board of Directors

Mihir R.Ghatalia





DRUGS & PHARMACEUTICALS LTD.

CTN No LgggggmHiggopicose

H. O.: 107,204, SAHAKAR BHAVAN, 340 / 48, N. N. STREET, MASJID BUNDER, MUMBAI - 400 009. ©: (022) 66312998 / 66154219 Fax: 66154219 E-mail: info@aareydrugs.com REGD. OFF. & FACTORY: E - 34, M.I.D.C., TARAPUR, BOISAR, DIST - THANE - 401506 ©: (02525) 271049 E-mail: corporate@aareydrugs.com Web: www.aareydrugs.com

DEF DIVISION

ANNEXURE - II

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 31ST DECEMBER'2015

,	PARTICULARS	9 MONTH	SENDED	3 MONTHS ENDED		
).		31.12.2015 DEF Division Unaudited	31.12.2014 Unaudited	31.122015 Unaudited	30.09.2015 Unaudited	31.12.2014 Unaudited
		2747.87	4087.55	1266.61	644 27	1582.99
1	Net Income from Sales/Services	2705.32	3976.49	1261.67	632 13	1554.76
2	Cost of Sales/Services	2703.32				
	a Increase/Decrease in stock in					
	trade & work in progress					
	b Consumption of Raw Materials					
	c. Purchase of traded goods					
	d Other Expenditure		111.06	4.94	12.14	28.23
3	Gross Profit (1-2)	42.55	44.60	5.81	8.82	6.20
4	General Administrative Expenses	28.64	10.46	5.20	2 01	3.80
5	Selling and Distribution Expenses	9.99	12.76	4.46	4.37	6.72
6	Depreciation	13.08	43.24	-10.53	-3.06	11.51
7	Operating Profit before Interest (3) -	-9.16	43.24	10.00		
	(4+5+6)	20.11	25.41	8.06	8.03	8.84
8	Interest	23.14	0	0	0	0
9	Exceptional Items	0	17.83	-18.59	-11.09	2.67
10	Operating Profit after Interest and	-32.3	17.00	-10.00		
	Exceptional Items (7-8-9)		0.70	22.60	20.14	1.93
11	Other Income	57.24	3.78	4.01	9.05	4.60
12	Profit (+)/Loss (-) from Ordinary	24.94	21.61	4.01	0.00	
	Activities before tax (10+11)		0.00	0.00	0	0.00
13	Tax Expenses	0.00	0.00	4.01	9.05	4.60
14	Net Profit (+)/Loss (-) from ordinary	24.94	21.61	4.01	3.00	
1-4	Activities after tax (12-13)			0	0	0
15	Extraordinary items (net of tax expenses)	0	0	4.01	9.05	4.60
16	Net Profit(+)/Loss(-) for the period(14-15)	24.94	21.61			4 1681.46
17	Paid-up equity share capital-Rs.10/-	1681.4684		4 1661.4004	1001:100	
18	Reserves excluding revaluation					
	reserves(as per balance sheet) of					
	previous accounting year to be			7		
	given in column (5)			_		
19	- (500)			0.02	0.05	0.03
	a) Basic and diluted EPS before	0.14	0.13	0.02	0.01	
	Extraordinary items for the period,					
	for the year to date and for the previous					
	year (not to be annualized)					
	b) Basic and diluted EPS after					
	Extraordinary items for the period,					
	for the year to date and for the previous					
	year (not to be anualized)					
				#40010	704788	71601
2	Number of shares	716013			_	, ,
	Percentage of Shareholding	42.58%	42.58%	42.58%	41.927	42.00

Note

DEF Division comprises of the following products:-

1 Acetic Acid

2 Butyl Acetate Monomer

3 Toluene

4 Vinyl Acetate Monomer

Place: Tarapur

Date: 15th February'2016

v. as

By Order of the Board of Directors

Mihir R.Ghatalia Managing Director

DMKH & CO.

Chartered Accountants

C-9, Sanjay Apartment, S.V.P. Road Near Gokul Hotel, Borivali (West) Mumbai -400092.

(+91-2228916494/95

Email ID:-dmkhco@gmail.com



The Board of Directors,

AAREY DRUGS AND PHARMACEUTICALS LIMITED, E-34, M.I.D.C., TARAPUR, BOISAR THANE-401506

Re: Limited Review of the Financial Result for the quarter ended 31st December 2015.

We have reviewed the accompanying statement of unaudited financial results of AAREY DRUGS & PHARMACEUTICALS LIMITED for the Quarter and period ended 31st December 2015. This statement is the responsibility of the Company's Management and has been approved by the Board of Director. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Review Financial information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards specified under section 133 of companies Act, 2013, Read with Rule 7 of the companies (Accounts) Rules, 2014 and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For DMKH & Co.

Chartered Accountants

FRN 116886W

CA. Manish Kankani

Partner

M.No. 158020

Place: Mumbai Date: 15/02/2016



DMKH & CO.

Chartered Accountants

C-9, Sanjay Apartment, S.V.P. Road Near Gokul Hotel, Borivali (West) Mumbai -400092.

(+91-2228916494/95

Email ID:-dmkhco@gmail.com



The Board of Directors,

AAREY DRUGS AND PHARMACEUTICALS LIMITED, E-34, M.I.D.C., TARAPUR, BOISAR THANE-401506

Re: LimitedReview of the Financial Result for the quarter ended 31st December 2015.

We have reviewed the accompanying statement of unaudited financial results of **AAREY DRUGS & PHARMACEUTICALS LIMITED** for the Quarter and period ended 31st December 2015. This statement is the responsibility of the Company's Management and has been approved by the Board of Director.Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Review Financial information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards specified under section 133 of companies Act, 2013, Read with Rule 7 of the companies (Accounts) Rules, 2014 and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For DMKH & Co.

Chartered Accountants

FRN 116886W

CA. Manish Kankan

Partner

M.No. 158020 Place: Mumbai Date: 15/02/2016